Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Stock analysts at SunTrust Banks lowered their Q4 2017 EPS estimates for Sarepta Therapeutics in a research report issued on Tuesday. SunTrust Banks analyst E. Nash now expects that the biotechnology company will earn ($0.73) per share for the quarter, down from their previous estimate of ($0.69). SunTrust Banks currently has a “Buy” rating and a $56.00 price objective on the stock.

Other equities analysts have also issued reports about the company. Credit Suisse Group set a $64.00 price objective on Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Leerink Swann restated a “buy” rating and set a $60.00 price target (up from $52.00) on shares of Sarepta Therapeutics in a research note on Tuesday, July 18th. BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Royal Bank Of Canada restated a “buy” rating and set a $60.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, June 22nd. Finally, Nomura restated a “buy” rating and set a $84.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, September 5th. One analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have assigned a buy rating to the stock. Sarepta Therapeutics currently has a consensus rating of “Buy” and an average target price of $64.34.

TRADEMARK VIOLATION NOTICE: “SunTrust Banks Weighs in on Sarepta Therapeutics, Inc.’s Q4 2017 Earnings (SRPT)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/12/suntrust-banks-weighs-in-on-sarepta-therapeutics-inc-s-q4-2017-earnings-srpt.html.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 1.17% during midday trading on Thursday, reaching $51.77. The company’s stock had a trading volume of 108,872 shares. Sarepta Therapeutics has a 12 month low of $26.26 and a 12 month high of $55.02. The stock’s 50-day moving average is $44.86 and its 200 day moving average is $36.84. The stock’s market capitalization is $3.33 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.46. The business had revenue of $35.01 million for the quarter, compared to analyst estimates of $22.52 million. During the same quarter last year, the business earned ($1.19) EPS. Sarepta Therapeutics’s revenue for the quarter was up 350000.0% compared to the same quarter last year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Prentiss Smith & Co. Inc. increased its position in shares of Sarepta Therapeutics by 772.2% in the 2nd quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 3,166 shares in the last quarter. Ameritas Investment Partners Inc. bought a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at $127,000. Cubist Systematic Strategies LLC increased its position in shares of Sarepta Therapeutics by 116.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,474 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Sarepta Therapeutics by 150.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 2,800 shares in the last quarter. Finally, Edge Wealth Management LLC bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at $175,000. Institutional investors and hedge funds own 65.41% of the company’s stock.

In related news, SVP Shamim Ruff sold 11,500 shares of the company’s stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $50.00, for a total value of $575,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Sandesh Mahatme sold 50,000 shares of the company’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $2,050,000.00. Following the completion of the sale, the chief financial officer now owns 41,736 shares of the company’s stock, valued at approximately $1,711,176. The disclosure for this sale can be found here. In the last 90 days, insiders sold 89,556 shares of company stock valued at $3,799,208. 9.60% of the stock is owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.